COVID-19 Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03TXY
|
|||
| Drug Name |
PMID28216367-compound-6d
|
|||
| Synonyms |
PMID28216367-C-6d
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Middle East Respiratory Syndrome (MERS) | Preclinical | [1] | Severe acute respiratory syndrome (SARS) | Preclinical | [1] |
| Therapeutic Class |
Antiviral Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Target | Top | |||
|---|---|---|---|---|
| Target(s) | MERS-CoV 3C-like proteinase (3CLpro) | Target Info | Inhibitor | [1] |
| Peptidomimetic inhibitor of enterovirus 3Cpro (compound 6d) inhibits 3CLpro of MERS-CoV with IC50 values 1.7 microM. | ||||
| SARS-CoV 3C-like protease (3CLpro) | Target Info | Inhibitor | [1] | |
| Peptidomimetic inhibitor of enterovirus 3Cpro (6d) inhibits 3CLpro of SARS-CoV with IC50 values 0.2 microM. | ||||
| References | Top | |||
|---|---|---|---|---|
| 1 | Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors. Antiviral Res. 2017 May;141:101-106. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.